Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment guidelines news

Show

From To
Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds

A study measuring HIV drug resistance at two timepoints in Kenyan patients on second-line, protease inhibitor-based regimens has found very high levels of drug resistance in people with

Published
15 hours ago
By
Gus Cairns
US doctors’ organisation endorses event-based PrEP for the first time

For the first time, a US-based professional HIV body has published guidelines endorsing event-based or so-called ‘on-demand’ pre-exposure prophylaxis (PrEP) as an alternative to daily dosing. The International

Published
19 September 2018
By
Gus Cairns
Focus on HIV-2 Infection: A Clinician Roundtable

Infectious Disease Advisor interviewed the following experts to discuss the challenges and clinical implications pertaining to HIV-2.

Published
04 September 2018
From
Infectious Disease Advisor
Why the world may force women to choose: No birth control, no ARVs

A new drug could save 25 000 women living with HIV but could it come at the cost of their babies lives?

Published
22 August 2018
From
Bhekisisa
Why are some countries slow to implement HIV treatment guidelines?

Differences in countries’ economic prosperity and HIV prevalence do not explain the speed with which they update their national treatment policies and guidelines, but factors related to

Published
25 July 2018
By
Roger Pebody
Dolutegravir-based ART recommended for all – if reliable contraception is available

The World Health Organization (WHO) has issued new antiretroviral treatment guidelines recommending dolutegravir-based treatment as the preferred first-line treatment option for all adults, adolescents and children, including

Published
24 July 2018
By
Keith Alcorn
Brazil confirms dolutegravir is the most effective drug for first-line HIV treatment

People receiving dolutegravir-based antiretroviral treatment in Brazil’s national treatment programme were far more likely to have a fully suppressed viral load six months after starting treatment, according

Published
24 July 2018
By
Keith Alcorn
Australian doctors to tell HIV patients that 'undetectable=untransmissible'

In what has been seen as major win for HIV advocates, the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) has released a guide to help doctors understand the ‘Undetectable=Untransmittable (U=U)’ campaign.

Published
24 July 2018
From
Gay Star News
Dolutegravir: need to consider all pros and cons before switching in pregnancy

A young pregnant woman who switched from dolutegravir (DTG)-based ART, in response to the neural tube defect safety signal, experienced viral rebound on her new regimen. She needed to be switched back to DTG to achieve re-suppression and prevent vertical transmission.

Published
11 July 2018
From
HIV i-Base
All-access for blockbuster TB drug in South Africa

The country made history on Monday when the health department announced that all drug-resistant tuberculosis (DR-TB) patients will be eligible to receive the new medicine, bedaquiline. “The Department of Health’s [DoH] commitment on bedaquiline is momentous globally and marks a new era of DR-TB management where we are really prioritising the patient,” Doctors Without Borders’ Dr Anja Reuters told Health-e News.

Published
19 June 2018
From
Health-e
← First12345...37Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.